Nanohmics SBIR Phase 2: DNA Aptamer-3'-Fc Conjugates for Treatment of Syphilis.
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $1,500,000 to $3,000,000
- Set-aside
- Total Small Business
Forecast facts
- Anticipated award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Points of contact
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health is forecasting a new total small business Phase 2 SBIR award titled "Nanohmics SBIR Phase 2: DNA Aptamer-3'-Fc Conjugates for Treatment of Syphilis," with an estimated solicitation release date of September 1, 2026 and an estimated award date of October 1, 2026, both preceding the November 14, 2026 posting date. The award funds further development of an alternative to benzathine penicillin (BPG), the current syphilis standard of care, which is not available orally and faces frequent shortages in the US and globally. Activities may include but are not limited to PK/PD evaluation of promising candidates in animal models, PK/PD modeling to extrapolate human-equivalent exposure in mothers and fetuses, PK/PD modeling of drug-drug interactions with antiretroviral therapies, continued development and validation of candidate drugs, and definition of dosing regimens for different populations and disease stages.
The estimated award value range is $1.5 million to $3 million, while the description states the Phase 2 award is for up to $1.5 million. The requirement falls under NAICS 541715, Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology). Points of contact are Callie Prassinos, Contracting Officer, at callie.prassinos@nih.gov or +12406695155, and Jonathan Glock at jglock@niaid.nih.gov.
Forecast text
A Phase 2 SBIR award for up to $ 1,500,000 to further develop an alternative treatment for syphilis, other than the current standard of care benzathine penicillin (BPG). BPG is not available orally and shortages of BPG are common in the US and globally. Alternative therapies to BPG are urgently needed that address these and other issues with this current treatment as acquired and congenital syphilis rates are increasing rapidly. Recent advances in the ability to culture T. pallidum mean that identification of alternatives to BPD for the treatment of syphilis is now more feasible than has been possible in the past, as now in vitro assays can assist in identification of promising candidates with efficacy against this bug. Activities under this award may include but are not limited to Evaluation of PK/PD of promising candidates in animal models, PK/PD modelling to extrapolate human equivalent exposure in mothers and their fetuses, PK/PD modelling of drug-drug interactions with anti-retroviral therapies, continued development and validation of candidate drugs, and definition of dosing regimen for different populations and stages of disease.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast